The treatment of endometrial cancer is mainly based on surgery, supplemented by radiotherapy, chemotherapy, hormone and other comprehensive treatments. At present, there is no stipulation on the number of lymph node dissection in the major diagnostic and treatment guidelines for endometrial cancer, and the scope of lymph node dissection in surgery is decided according to the clinical stage and classification. 1. Clinical stage I (endometrial cancer confined to uterine body): extrafascial total hysterectomy with double adnexectomy ± pelvic and abdominal para-aortic lymph node dissection, and sentinel lymph node mapping biopsy can be considered. 2. Clinical stage II (endometrial cancer invading the interstitium of the cervix): wide/modified wide hysterectomy + bilateral adnexectomy + pelvic and abdominal para-aortic lymphadenectomy. 3. Clinical stage II and above: comprehensive treatment should be the mainstay. Tumor cytoreduction including hysterectomy + bilateral adnexectomy is recommended, and neoadjuvant chemotherapy followed by surgery can also be considered. 4. Type II endometrial cancer: including plasma adenocarcinoma, clear cell carcinoma and carcinosarcoma. Operative modality: total hysterectomy with double adnexectomy and pelvic lymph node and para-abdominal aortic lymph node dissection + salpingo-oophorectomy + peritoneal multi-point biopsy. Pelvic lymph nodes and para-abdominal aortic lymph nodes at least to the level of the inferior mesenteric artery (preferably to the level of the renal vessels) are evaluated for those who meet the criteria of positive pelvic lymph nodes, deep myxoid infiltration, G3, plasma adenocarcinoma, clear cell adenocarcinoma, or carcinosarcoma. Lymph node dissection facilitates assessment of metastasis and staging. Currently, the number of lymph nodes is not specified in the major endometrial cancer guidelines, and the number and extent of lymph node dissection for endometrial cancer should be determined by the physician’s comprehensive evaluation.